NPI: 1003070285 · DOTHAN, AL 36301 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 07/16/2008
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 07/16/2008 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 14,226 | $305K |
| 2019 | 12,270 | $308K |
| 2020 | 13,208 | $212K |
| 2021 | 2,585 | $92K |
| 2022 | 2,911 | $81K |
| 2023 | 772 | $13K |
| 2024 | 549 | $5K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 15,356 | 1,205 | $681K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 14,917 | 711 | $286K |
| J1756 | Injection, iron sucrose, 1 mg | 2,743 | 496 | $23K |
| 83970 | 454 | 362 | $10K | |
| J1270 | Injection, doxercalciferol, 1 mcg | 9,888 | 742 | $6K |
| A4657 | Syringe, with or without needle, each | 731 | 605 | $3K |
| 83550 | 458 | 356 | $2K | |
| 83540 | 458 | 356 | $1K | |
| 82728 | 292 | 231 | $1K | |
| 82108 | 69 | 61 | $1K | |
| 85041 | 547 | 449 | $717.34 | |
| 85048 | 547 | 449 | $667.50 | |
| 90674 | 13 | 12 | $84.39 | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 48 | 38 | $0.00 |